Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medical technology company Osteopore (OSX) has welcomed Jack O’Mahony to the company as its new Board Advisor
  • Mr O’Mahony has over four decades of medical device experience and has held several leadership roles
  • Notably, Jack is the former President and CEO of Cochlear, a medical device company specialising in hearing aids
  • The new Board Advisor will assist with developing business strategies and requirements for targeting certain markets
  • Osteopore is up 6.67 per cent and shares are trading for 80 cents each

Medical technology company Osteopore (OSX) has welcomed Jack O’Mahony to the company as its new Board Advisor.

Jack has over 40 years of global experience in the medical devices industry and, notably, is the former President and CEO of Cochlear.

During his time at Cochlear, Mr O’Mahony implemented various growth strategies and infrastructure improvements as CEO.

“Jack brings significant international experience and relationships to Osteopore that will further support Osteopore’s international expansion,” Osteopore Chairman Brett Sandercock said.

Prior to his time at Cochlear, Jack was the President Asia Pacific of Synthes before it was sold to Johnson and Johnson, a multi-national medical device company, for US$ 22.3 billion (A$32.7 billion).

Additionally, he was President of Howmedica and International President of Stryker Corp based in Europe.

Most recently, Jack was the President for the International Division of Signature Orthopaedics which is an Australian medical device business.

“We are delighted to have appointed an advisor to the Board with such deep and relevant experience, particularly in the medical device and orthopaedic sectors,” Brett said.

O’Mahony will advise the Board and work the Goh Khoon Seng, CEO of Osteopore, to assist with the development of business strategies and requirements for targeting certain markets.

Having a highly experienced new addition to the Board comes at a strategic time when Osteopore is looking to establish new distribution agreements and increase product revenue.

Osteopore is up 6.67 per cent and shares are trading for 80 cents each at 3:57 pm AEDT.

OSX by the numbers
More From The Market Herald
Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson

" Anteris Technologies (ASX:AVR) eyes $5m for DurAVR

Anteris Technologies (AVR) has placed 625,000 new ordinary shares to Melbourne-based global investor L1 Capital to raise $5 million.
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo (ASX:AT1) approved to supply and advertise HIV Self-Test

Atomo Diagnostics (AT1) can now supply its HIV self-test to a greater variety of organisations and begin advertising thanks to recent changes made
Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley

" Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Starpharma (SPL) has penned an initial deal to distribute and supply its VIRALEZE antiviral nasal spray in Vietnam.
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett

" Paradigm Biopharmaceuticals (ASX:PAR) amends clinical trial

Paradigm Biopharmaceuticals (PAR) has made amendments to its clinical trial protocol for knee osteoarthritis treatment.